Method for synthesis of carbazole derivatives for treatment of amyotrophic lateral sclerosis
Patent Information
- Application Number
- IN202511115032
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2025-11-21
- Publication Date
- 2026-10-09
- Estimated Expiration
- 2045-11-21
AI Technical Summary
Current treatments for amyotrophic lateral sclerosis (ALS) associated with mutant superoxide dismutase 1 (SOD1) protein aggregation are ineffective, highlighting the need for small molecules that can specifically prevent or reverse this aggregation.
A method for synthesizing carbazole derivatives by reacting carbazole with phenylchloroformate, followed by refluxing with hydrazine hydrate and coupling with a substituted phenyl isocyanate/isothiocyanate, which are then tested for their ability to inhibit SOD1 protein aggregation using neuronal cell models and assays like Thioflavin T fluorescence and Dynamic Light Scattering.
The synthesized carbazole derivatives effectively inhibit SOD1 protein aggregation, reducing cytotoxicity and apoptosis in neuronal cells, thereby potentially slowing ALS progression.
Abstract
Description
FIELD OF THE DISCLOSURE
[0001] The present invention relates to the field of medicinal chemistry,neuropharmacology, and neurodegenerative disease research. More particularly, theinvention concerns the method of synthesis, and biological evaluation of carbazolebasedderivatives that act as inhibitors of mutant human superoxide dismutase 1(hSOD1) protein aggregation.BACKGROUND
[0002] The subject matter discussed in the background section should not beassumed to be prior art merely as a result of its mention in the background section.Similarly, a problem mentioned in the background section or associated with thesubject matter of the background section should not be assumed to have beenpreviously recognized in the prior art. The subject matter in the background sectionmerely represents different approaches, which in and of themselves may alsocorrespond to implementations of the claimed technology.
[0003] Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease,is a progressive and fatal neurodegenerative disorder that primarily affects the motorneurons in the brain and spinal cord. The loss of these neurons may lead to muscleweakness, paralysis, and eventually the inability to control voluntary muscles. Mostpatients survive only three to five years after disease onset. The ALS may occur intwo forms: familial (fALS), which has a genetic background, and sporadic (sALS),which occurs without a family history. Among the genetic causes, mutations in thesuperoxide dismutase 1 (SOD1) gene account for nearly 20% of familial ALS cases.Further, the SOD1 is a key antioxidant enzyme that may help reduce oxidative stressin cells. The mutations in SOD1 may cause the protein to misfold and form toxicaggregates that damage neurons. These aggregates share structural similarities withamyloid fibrils and contribute to neuroinflammation and cell death, a hallmark ofALS pathology.
[0004] Research has shown that the aggregation of mutant SOD1 proteins such asA4V, G85R, and G93A, plays a major role in the progression of ALS. Thesemutations interfere with the normal structure and stability of the SOD1 enzyme,leading to dimer dissociation, improper metal binding, and the formation ofamyloid-like fibrils. Despite years of research, there are still no effective treatmentsfor SOD1-associated ALS. Various approaches, including inhibiting proteinaggregation, stabilizing native protein structures, and reducing oxidative stress,have been explored to slow disease progression. However, most strategies haveshown limited success, highlighting the urgent need for small molecules that mayspecifically prevent or reverse SOD1 aggregation.
[0005] According to the patent application number ZA202405217B titled as"Method for synthesizing and characterizing carbazole derivatives as mutant hsod1protein aggregation inhibitors" discloses "A method for synthesizing carbazolederivatives as mutant hSOD1 protein aggregation inhibitors, wherein the methodcomprises of: synthesizing carbazole derivatives upon reacting commerciallyaccessible carbazole with phenyl-chloroformate to obtain (9-Ethyl-9H-carbazol-3-yl)-carbamic acid phenyl ester, wherein phenyl ester derivative is refluxed withhydrazine hydrate to achieve key intermediate acid hydrazide which is coupled with4-substituted phenyl isocyanate / isothiocyanate to provide the carbazole derivatives;generating a plurality of superoxide dismutase 1 (SOD1) mutant plasmid cells uponmutating pET15b SOD1 WT plasmid; performing transformation of the generatedmutant plasmid cells into NEB 5-alpha competent E.coli cells, wherein thetransformed cells with mutant plasmids are purified to obtain purified hSOD1mutant proteins; an inhibiting the purified hSOD1 mutant protein aggregation,wherein the amount of aggregation is quantified using a thioflavin-T (ThT)fluorescence method".
[0006] According to the patent application number US20060194821A1 titled as"Compounds inhibiting the aggregation of superoxide dismutase-1" discloses about"The invention is directed to methods of inhibiting the rate at which superoxidedismutse-1 (SOD) aggregates using compounds that stabilize SOD dimers. Themethods are useful in the study and therapy of amyotrophic lateral sclerosis. Theinvention also includes assays that may be used to identify compounds that stabilizedimers and SOD molecules that ha ve been modified for use in these assays".
[0007] Any of the above prior art do not discloses a process for the synthesis ofcarbazole derivatives, which includes reacting carbazole with phenylchloroformateto obtain (9-Ethyl-9H-carbazol-3-yl)-carbamic acid phenyl ester and the reaction iscarried out in DCM with TEA and stirred at room temperature for 6 hours. Any ofthe above prior do not include refluxing the phenyl ester derivative with hydrazinehydrate in 1,4-dioxane for 8 hours to obtain the key intermediate acid hydrazide.Any of the above prior art do not include coupling the acid hydrazide with 4-substituted phenyl isocyanate / isothiocyanate in acetonitrile under reflux to obtainthe carbazole derivatives. Any of the above prior art do not involve PCR-based site15directed mutagenesis to generate plasmids containing ALS-associated mutations.Any of the above prior art do not include purification of mutant proteins using a Ni-NTA column. Any of the above prior art do not include assessing the inhibitoryactivity of compounds (carbazole derivatives) against SOD1 mutant proteins usingThioflavin T (ThT)-based fluorescence assays.
[0008] Any of the above prior art do not include assessing the potential of selectedcompounds to inhibit aggregation of mutant SOD1 proteins using electronmicroscopy. Any of the above prior art do not include determining the size profilesof aggregation under various conditions using Dynamic Light Scattering (DLS).Any of the above prior art do not include assessing the ability selected compoundsto prevent aggregation in a neuronal cell line-based model. Any of the above priorart do not include cloning and generating stable transfected cell lines with thepCDH-hSOD1 G85R plasmid.
[0009] Any of the above prior art do not include studying the cytotoxic effects ofselected compounds on the viability of Neuro-2a cells using the MTT assay. Any ofthe above prior art do not include determining the potential of selected compoundsto rescue Neuro-2a cells from hSOD1 G85R-associated cytotoxicity. Any of theabove prior art do not include testing the ability of selected compounds to moderatehSOD1 G85R-associated ROS generation in Neuro-2a cells. Any of the above priorart do not include testing the ability of the compounds to rescue Neuro-2a cells fromhSOD1 G85R aggregation-induced apoptosis using Western blotting and FACS.
[0010] Therefore, there is a need to provide a method for the synthesis and testingof carbazole derivatives as potential inhibitors of mutant human SOD1 aggregation.OBJECTIVES OF THE INVENTION
[0011] An objective of the invention is to provide a method for the synthesis ofcarbazole derivatives for treatment of amyotrophic lateral sclerosis.
[0012] Furthermore, an objective of the present invention is to synthesize andcharacterize a series of novel carbazole derivatives as potential mutant SOD1protein aggregation inhibitors.
[0013] Furthermore, the objective of the present invention to assess binding abilitiesof novel carbazole derivatives with different hSOD1 mutants (G85R, A4V, G93A)associated with fALS.
[0014] Furthermore, the objective of the present invention is to test the ability ofsynthesized compounds to prevent the aggregation of mutant hSOD1 mutantproteins (A4V, G85R and G93A).
[0015] Furthermore, the objective of the present invention is to perform PCR-basedsite-directed mutagenesis to generate plasmids containing mutations associated withALS.
[0016] Furthermore, the objective of the present invention is to purify mutantproteinsemploying a Ni-NTA column.
[0017] Furthermore, the objective of the present invention is to assess the inhibitoryactivity of the compounds (4-19) against SOD1 mutant protein by employingThioflavin T (ThT) based fluorescence assays.
[0018] Furthermore, the objective of the present invention is to assess the potentialof selected compounds to inhibit aggregation of mutant SOD1 proteins byemploying Electron microscopy.
[0019] Furthermore, the objective of the present invention is to determine the sizeprofiles of the aggregation under various conditions b y Dynamic Light Scattering.
[0020] Furthermore, the objective of the present invention is to asses of SG-9 andSG-10's ability to prevent aggregation in a neuronal cell line-based model.
[0021] Furthermore, the objective of the present invention is to clone and generatestable transfected cell lines with pCDH hSOD1 G85R plasmid.
[0022] Furthermore, the objective of the present invention is to study thecytotoxicity effect of compounds SG-9 and SG-10 on the viability of Neuro-2a cellsusing MTT assay.
[0023] Furthermore, the objective of the present invention is to determine thepotential of SG-9 and SG-10 to rescue Neuro-2a cells against hSOD1 G85Rassociated cytotoxicity.
[0024] Furthermore, the objective of the present invention is to test the ability ofcompounds SG-9 and SG-10 to moderate hSOD1 G85R associated ROS generationin Neuro-2a cells.
[0025] Furthermore, the objective of the present invention is to test the ability ofthe compounds to rescue Neuro-2a cells against hSOD1 G85R aggregation-inducedapoptosis by Western blotting and FACS.SUMMARY
[0026] The present invention relates to a method for the synthesis of carbazolederivatives for treatment of amyotrophic lateral sclerosis.
[0027] According to an aspect of the invention, a method for the synthesis ofcarbazole derivatives for treatment of amyotrophic lateral sclerosis is disclosed.Further, the method comprises a step of reacting carbazole withphenylchloroformate to obtain (9-ethyl-9H-carbazol-3-yl)-carbamic acid phenylester. Further, the reaction is carried out in dichloromethane (DCM) in the presenceof triethylamine (TEA) and the reaction mixture is stirred at room temperature for6 hours. Further the method comprises a step of reacting carbazole withphenylchloroformate to obtain (9-ethyl-9H-carbazol-3-yl)-carbamic acid phenylester. Further, the method comprises a step of refluxing the resulting phenyl esterderivative with hydrazine hydrate in 1,4-dioxane to obtain a key intermediate acidhydrazide. Further, the method comprises a step of refluxing the phenyl esterderivative with hydrazine hydrate for 8 hours in 1,4-dioxane to yield the acidhydrazide intermediate. Further, the method comprises a step of coupling the acidhydrazide with a 4-substituted phenyl isocyanate or 4-substituted phenylisothiocyanate in acetonitrile under reflux to obtain a carbazole derivativecompound. Further, the obtained carbazole derivative acts as a potential inhibitor ofhuman superoxide dismutase 1 (hSOD1) protein aggregation for the treatment ofAmyotrophic Lateral Sclerosis (ALS). Further, the obtained carbazole derivativeacts as a potential inhibitor of human superoxide dismutase 1 (hSOD1) proteinaggregation for the treatment of Amyotrophic Lateral Sclerosis (ALS).
[0028] According to another aspect of the invention, the present invention disclosesthe method of obtaining carbazole derivative which acts as a potential inhibitor ofhuman superoxide dismutase 1 (hSOD1) protein aggregation for the treatment ofAmyotrophic Lateral Sclerosis (ALS). The method further comprises evaluating theanti-aggregation effects of selected carbazole derivatives in a neuronal cell-basedmodel. The method further comprises a step of testing the inhibitory potential of thesynthesized carbazole derivatives against aggregation of mutant hSOD1 proteinsselected from A4V, G85R, and G93A.
[0029] According to another aspect of the present invention, the neuronal cell-basedmodel comprises Neuro-2a cells stably transfected with a pCDH-hSOD1 G85Rplasmid, and wherein the method further includes. Further the method comprises astep of determining the cytotoxic effects of the carbazole derivatives on Neuro-2acells using an MTT cell viability assay. Further the method comprises a step ofevaluating the protective effect of the carbazole derivatives by assessing their abilityto rescue Neuro-2a cells from hSOD1 G85R-induced cytotoxicity. Further themethod comprises a step of testing the ability of the compounds to moderate hSOD1G85R-associated reactive oxygen species (ROS) generation in Neuro-2a cells.Further the method comprises a step of evaluating the ability of the compounds torescue Neuro-2a cells from hSOD1 G85R aggregation-induced apoptosis usingWestern blotting and flow cytometry (FACS) analyses.BRIEF DESCRIPTION OF THE DRAWINGS
[0030] The accompanying drawings illustrate the embodiment of the system. Anyperson with ordinary skills in the art will appreciate that the illustrated elementboundaries (e.g., boxes, groups of boxes, or other shapes) in the figures representone example of the boundaries. It may be that in some examples one element maybe designed as multiple elements or that multiple elements may be designed as oneelement. In some examples, an element shown as an internal component of oneelement may be implemented as an external component in another, and vice versa.Furthermore, elements may not be drawn to scale. Non-limiting and non-exhaustivedescriptions are described with reference to the following drawings. Thecomponents in the figures are not necessarily to scale, emphasis instead being placedupon illustrating principles.
[0031] FIG. 1A illustrates a flow chart of showing a method for the synthesis ofcarbazole derivatives for treatment of amyotrophic lateral sclerosis, according to anembodiment of the present invention;
[0032] FIG. 1B illustrates a mechanism of preparation of synthesis ofphenylchloroformate, DCM, TEA, RT for 6h, Hydrazine hydrate, 1,4-dioxane,reflux for 8h and 4-Substituted phenyl isocyanate / isothiocyanate, Acetonitrile,reflux, according to an embodiment of the present invention;
[0033] FIG. 2A illustrates a graphical representation of 1H and 13C NMR ofcompound 12 (SG-9), according to an embodiment of the present invention;
[0034] FIG. 2B illustrates another graphical representation of 1H and 13C NMR ofcompound 12 (SG-9), according to an embodiment of the present invention
[0035] FIG. 2C illustrates another graphical representation of Mass spectra andHPLC chromatogram of compound 12 (SG-9), according to an embodiment of thepresent invention;
[0036] FIG. 2D illustrates another graphical representation of Mass spectra andHPLC chromatogram of compound 12 (SG-9), according to an embodiment of thepresent invention;
[0037] FIG. 3A illustrates a graphical representation of 1H and 13C NMR ofcompound 13 (SG-10), according to an embodiment of the present invention;
[0038] FIG. 3B illustrates a graphical representation of 1H and 13C NMR ofcompound 13 (SG-10), according to an embodiment of the present invention;
[0039] FIG. 3C illustrates a graphical representation of Mass spectra and HPLCchromatogram of compound 13 (SG-10), according to an embodiment of the presentinvention;
[0040] FIG. 3D illustrates a graphical representation of Mass spectra and HPLCchromatogram of compound 13 (SG-10), according to an embodiment of the presentinvention;
[0041] FIG. 4 illustrates pictorial representation of (a) restriction map of pET15bSOD1 plasmid, (b) restriction digestion of pET15b SOD1 plasmid, double digestionwith XbaI and EcoRI yields a pop out of 867bp while double cut with EcoRV yieldstwo bands of 1.8kb and 4.3kb and (c) comparison between the sequenced data ofWT SOD1 plasmid and SOD1 mRNA sequence reveals 100% sequence similarity,according to an embodiment of the present invention;
[0042] FIG. 5 illustrates a pictorial representation of (a) PCR reaction at 72 °C annealing temperature for A4V mutant and at 65 °C for G85R and G93A mutantwith 1ng and 10ng template, and Comparison between the sequenced data of SOD1mRNA sequence with plasmid reveals a single base change of (b) C to T for A4V,(c) G to C for G85R and (d) G to C for G93A mutant respectively, according to anembodiment of the present invention;
[0043] FIG. 6A illustrates a pictorial representation of IPTG concentration gradientat 20º C for 19hrs, according to an embodiment of the present invention;
[0044] FIG. 6B illustrates another pictorial representation of the SDS-PAGE of allthe fractions during hSOD1 A4V mutant protein purification, according to anembodiment of the present invention;
[0045] FIG. 6C illustrates another pictorial representation of the SDS-PAGE of allthe fractions during hSOD1 G85R mutant protein purification, according to anembodiment of the present invention;
[0046] FIG. 6D illustrates another pictorial representation of the SDS-PAGE of allthe fractions during hSOD1 G93A mutant protein purification, according to anembodiment of the present invention;
[0047] FIG. 6E illustrates another pictorial representation of the Western blot withhSOD1 antibody confirm purified proteins as mutant SOD1 proteins, according toan embodiment of the present invention;
[0048] FIG. 7A illustrates a tabular representation of the depicting percentageinhibition potencies of compounds (4-19) at 50μM concentration againstaggregation of mutant SOD1 protein (A4V, G85R and G93A), according to anembodiment of the present invention;
[0049] FIG. 7B illustrates a graphical representation of the mean fluorescenceintensities of ThT for mutant SOD1 proteins alone and with co-incubation of SG-9and SG-10, resulting in decreasing in the fluorescence intensity indicates decreasein protein aggregation, according to an embodiment of the present invention;
[0050] FIG. 8 illustrates a pictorial representation of transmission electronmicrographs displaying a reduction in the mutant SOD1 protein aggregation in thetreated groups in comparison with the aggregated sample, according to anembodiment of the present invention;
[0051] FIG. 9A illustrates a graphical representation of size distribution plots ofuntreated and treated samples of SOD1 A4V mutant protein, according to anembodiment of the present invention;
[0052] FIG. 9B illustrates a graphical representation of size distribution plots ofuntreated and treated samples of SOD1 G85R mutant protein, according to anembodiment of the present invention;
[0053] FIG. 9C illustrates a graphical representation of Size distribution plots ofuntreated and treated samples of SOD1 G93A mutant protein, according to anembodiment of the present invention;
[0054] FIG. 10 illustrates a graphical representation of percentage viabilities atvarious concentrations of tested compounds SG-9 and SG-10, according to anembodiment of the present invention;
[0055] FIG. 11A illustrates a graphical representation of percentage cell viabilityupon treatment of MG-132 with and without the pre-treatment of differentconcentrations of SG-9 and SG-10, according to an embodiment of the presentinvention;
[0056] FIG. 11B illustrates a pictorial representation of phase contrast microscopypictures also depict similar conclusions, according to an embodiment of the presentinvention;
[0057] FIG. 12 illustrates a graphical representation of pre-treatment with SG-9 andSG-10 before the treatment of MG-132 protects cells from SOD1 G85Raggregation-associated toxicity, according to an embodiment of the presentinvention; and
[0058] FIG. 13 illustrates a graphical representation of (a) pre-treatment with SG-9and SG-10 rescued N2a cells from hSOD1 G85R aggregation-induced apoptosis,and (b) SG-9 and SG-10 restored the expression of anti-apoptotic proteins such asBcl-2 and Xiap, according to an embodiment of the present invention.DETAILED DESCRIPTION
[0059] Some embodiments of this disclosure, illustrating all its features, will nowbe discussed in detail. The words "comprising," "having," "containing," and"including," and other forms thereof, are intended to be equivalent in meaning andbe open ended in that an item or items following any one of these words is not meantto be an exhaustive listing of such item or items or meant to be limited to only thelisted item or items. It must also be noted that as used herein and in the appendedclaims, the singular forms "a," "an," and "the" include plural references unless thecontext clearly dictates otherwise.
[0060] Although any systems and methods similar or equivalent to those describedherein can be used in the practice or testing of embodiments of the presentdisclosure, the preferred, systems and methods are now described. Embodiments ofthe present disclosure will be described more fully hereinafter with reference to theaccompanying drawings in which like numerals represent like elements throughoutthe several figures, and in which example embodiments are shown. Embodimentsof the claims may, however, be embodied in many different forms and should notbe construed as limited to the embodiments set forth herein. The examples set forthherein are non-limiting examples and are merely examples among other possibleexamples.
[0061] Embodiments of the present invention discloses a method for the synthesisof carbazole derivatives. Embodiments of the present invention may comprise a stepof reacting carbazole with phenylchloroformate to obtain (9-ethyl-9H-carbazol-3-yl)-carbamic acid phenyl ester. Embodiments of the present invention may comprisea step of refluxing the resulting phenyl ester derivative with hydrazine hydrate in1,4-dioxane to obtain a key intermediate acid hydrazide. Embodiments of thepresent invention may comprise the step of refluxing the phenyl ester derivativewith hydrazine hydrate for 8 hours in 1,4-dioxane to yield the acid hydrazideintermediate. Embodiments of the present invention may comprise a step ofcoupling the acid hydrazide with a 4-substituted phenyl isocyanate or 4-substitutedphenyl isothiocyanate in acetonitrile under reflux to obtain a carbazole derivativecompound.
[0062] Embodiments of the present invention may comprise a step of evaluating theanti-aggregation effects of selected carbazole derivatives in a neuronal cell-basedmodel. Embodiments of the present invention may comprise a step of testing theinhibitory potential of the synthesized carbazole derivatives against aggregation ofmutant hSOD1 proteins selected from A4V, G85R, and G93A. Embodiments of thepresent invention may comprise a step of determining the cytotoxic effects of thecarbazole derivatives on Neuro-2a cells using an MTT cell viability assay.Embodiments of the present invention may comprise a step of evaluating theprotective effect of the carbazole derivatives by assessing their ability to rescueNeuro-2a cells from hSOD1 G85R-induced cytotoxicity. Embodiments of thepresent invention may comprise a step of testing the ability of the compounds tomoderate hSOD1 G85R-associated reactive oxygen species (ROS) generation inNeuro-2a cells. Embodiments of the present invention may comprise a step ofevaluating the ability of the compounds to rescue Neuro-2a cells from hSOD1 G85Raggregation-induced apoptosis using Western blotting and flow cytometry (FACS)analyses.
[0063] FIG. 1A illustrates a flow chart of showing a method (100) for the synthesisof carbazole derivatives, according to an embodiment of the present invention.
[0064] In some embodiments, the method (100) for the synthesis of carbazolederivatives is disclosed. Further, the method (100) may comprise a step of reactingcarbazole with phenylchloroformate to obtain (9-ethyl-9H-carbazol-3-yl)-carbamicacid phenyl.
[0065] In some embodiments, a method (100) for the preparation of carbazolederivatives is disclosed. The method (100) provides an efficient and reproducibleapproach to synthesize carbazole derivatives, which may be useful inpharmaceuticals, organic electronics, and chemical research. The method aims toimprove yield and purity while being straightforward and scalable.
[0066] In some embodiments, the method (100) may comprise a step (102) ofreacting carbazole with phenylchloroformate. The Carbazole acts as a nucleophile,and phenylchloroformate serves as the electrophilic reagent in this reaction. Thereaction is typically carried out under controlled temperature and suitable solventconditions to facilitate the formation of the desired intermediate. In someembodiments, the reaction may be carried out in dichloromethane (DCM) in thepresence of triethylamine (TEA) and the reaction mixture is stirred at roomtemperature for 6 hours
[0067] Further, as a result of the reaction, (9-ethyl-9H-carbazol-3-yl)-carbamic acidphenyl ester is obtained. This compound represents an important intermediate forfurther chemical modifications. The process allows for selective functionalizationat the 3-position of the carbazole ring, which may be used for subsequent synthesisof diverse carbazole derivatives. The disclosed method (100) is advantageous dueto its simplicity, reproducibility, and potential for scale-up. The process minimizesside reactions and provides a high-purity product suitable for further syntheticapplications. This method (100) may also be adapted for synthesizing othercarbazole-based compounds by varying the starting reagents or reaction condition.
[0068] In some embodiments, the method (100) may comprise a step of refluxing(104) the resulting phenyl ester derivative with hydrazine hydrate in 1,4-dioxane. Inthis step, the phenyl ester derivative undergoes nucleophilic substitution withhydrazine hydrate to form the corresponding acid hydrazide. The refluxing processensures continuous interaction between the reactants at elevated temperature, whichdrives the reaction to completion and prevents incomplete conversion of the startingmaterial.
[0069] The solvent, 1,4-dioxane, plays a critical role in the reaction by dissolvingboth the phenyl ester and hydrazine hydrate, thereby providing a homogeneousreaction medium. The choice of 1,4-dioxane also helps in controlling the reactionrate and temperature, minimizing the possibility of side reactions or degradation ofsensitive functional groups present in the phenyl ester derivative.
[0070] In some embodiments, the method (100) comprises refluxing the phenylester derivative with hydrazine hydrate for a period of 8 hours. This reaction timehas been found to be sufficient to achieve complete conversion to the acid hydrazideintermediate. Further, monitoring the reaction over this duration ensuresconsistency, reproducibility, and high yield, making the process suitable for bothlaboratory and industrial-scale synthesis.
[0071] As a result of this process, the key intermediate, acid hydrazide, is obtainedin good yield and with high purity. The intermediate is stable under the reactionconditions and may be directly used in subsequent synthetic steps for the preparationof various carbazole-based derivatives. The method (100) therefore provides areliable and practical approach to obtain essential intermediates without requiringcomplex purification steps.
[0072] The disclosed method (100) is advantageous because it is straightforward,reproducible, and uses readily available reagents. The controlled refluxingconditions and suitable solvent choice allow for efficient formation of the acidhydrazide intermediate while minimizing side reactions. Additionally, the processmay be adapted to synthesize related hydrazide derivatives by altering the startingphenyl ester, providing versatility and broad applicability in synthetic chemistry.
[0073] In some embodiments, the method (100) may comprise a step (106) ofcoupling the acid hydrazide with a 4-substituted phenyl isocyanate or 4-substitutedphenyl isothiocyanate in acetonitrile under reflux to obtain a carbazole derivativecompound.
[0074] In some embodiments, the present invention provides a method (100) for thesynthesis of carbazole derivative compounds. The method (100) involves using thepreviously obtained acid hydrazide as a key intermediate. The process is designedto be simple, reproducible, and suitable for preparing diverse carbazole-basedcompounds with high efficiency and purity.
[0075] The step (106) of coupling the acid hydrazide with a 4-substituted phenylisocyanate or a 4-substituted phenyl isothiocyanate. In this step, the acid hydrazidereacts with the substituted phenyl isocyanate or isothiocyanate under suitableconditions to form the desired carbazole derivative. This reaction allows selectiveattachment of the phenyl group to the hydrazide moiety.
[0076] The reaction is carried out in acetonitrile, which acts as a suitable solventproviding a homogeneous medium for the reaction. The refluxing the reactionmixture ensures that the temperature is maintained at the solvent's boiling point,thereby promoting complete reaction between the acid hydrazide and the substitutedphenyl isocyanate or isothiocyanate.
[0077] Further, as a result, the carbazole derivative compound is obtained in goodyield and high purity. The method (100) is advantageous due to its simplicity,reproducibility, and ability to produce structurally diverse carbazole derivatives byvarying the substituents on the phenyl isocyanate or isothiocyanate. This approachprovides a reliable and practical pathway for synthesizing carbazole-basedcompounds for further chemical or pharmaceutical applications.
[0078] In some embodiments, the carbazole derivative obtained by the disclosedmethod (100) acts as a potential therapeutic agent. The compound has been foundto inhibit the aggregation of human superoxide dismutase 1 (hSOD1) protein, whichis a critical factor in the onset and progression of Amyotrophic Lateral Sclerosis(ALS). The inhibition of hSOD1 aggregation may help in maintaining the normalfunctional state of the protein, thereby potentially reducing cellular toxicity andpreventing the formation of harmful protein aggregates in motor neurons.
[0079] Further, the ability of the carbazole derivative to target hSOD1 aggregationmay make it particularly useful for the treatment or management of ALS. Thecompound may be formulated into pharmaceutical compositions suitable foradministration to patients, either alone or in combination with other therapeuticagents. This provides a promising approach for slowing down the progression ofALS and improving the quality of life of affected individuals. Moreover, thedisclosed compound may also serve as a lead molecule for the development ofstructurally related derivatives with enhanced activity and selectivity againsthSOD1 aggregation.
[0080] In some embodiments, the present invention provides the method (100) thatmay comprise a step (108) of evaluating the anti-aggregation effects of selectedcarbazole derivatives in a neuronal cell-based model. This evaluation step may becarried out to determine the biological activity of the synthesized compounds andto confirm their ability to inhibit protein aggregation in living cells. The study mayhelp in understanding the therapeutic potential of the carbazole derivatives fortreating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).
[0081] The method (100) involves treating cultured neuronal cells with the selectedcarbazole derivatives under controlled laboratory conditions. The cells are thenmonitored for changes in protein aggregation behavior, particularly for aggregationof human superoxide dismutase 1 (hSOD1) or other disease-related proteins.Various analytical and imaging techniques, such as fluorescence microscopy orbiochemical assays, may be used to observe and measure the reduction in proteinaggregation after treatment.
[0082] The results obtained from this cell-based evaluation provide valuableinformation regarding the effectiveness and safety of the carbazole derivatives.Further, the compounds that show significant inhibition of protein aggregation maybe considered as potential lead molecules for further development. The method(100) therefore offers a reliable and reproducible approach to assess the biologicalactivity of carbazole derivatives and supports their possible application intherapeutic research.
[0083] In some embodiments, the method (100) may comprise a step (110) oftesting the inhibitory potential of the synthesized carbazole derivatives againstaggregation of mutant hSOD1 proteins selected from A4V, G85R, and G93A.
[0084] In some embodiments, the method (100) may include a step (110) of testingthe inhibitory potential of the synthesized carbazole derivatives against aggregationof mutant human superoxide dismutase 1 (hSOD1) proteins selected from thevariants A4V, G85R and G93A. In this step, each of the mutant hSOD1 proteins isused in an aggregation assay to assess whether the carbazole derivatives may reduceor prevent their aggregation. The selection of these specific mutants A4V, G85Rand G93A is based on their known high propensity to form aggregates in the contextof Amyotrophic Lateral Sclerosis.
[0085] In the testing step (110), the synthesized carbazole derivatives are appliedunder controlled experimental conditions to the mutant hSOD1 proteins, and thelevel or rate of aggregation is measured. The assay may involve quantifying theformation of insoluble aggregates, monitoring changes in the soluble versusinsoluble protein fractions, or observing aggregate‐formation by imaging orbiochemical means. The data obtained in this way provides an indicator of howeffective a given carbazole derivative is at inhibiting the aggregation of each mutanthSOD1.
[0086] The results of this testing step (110) enable the identification of thosecarbazole derivatives which show significant inhibitory activity against theaggregation of the selected mutant hSOD1 proteins. Such derivatives may then beconsidered as lead compounds for further development. This approach thereforesupports the objective of the invention to provide carbazole‐based compoundscapable of treating or managing conditions associated with hSOD1 aggregation, byselecting and advancing the most promising inhibitors.
[0087] In some embodiments, the method (100) may comprise a step of evaluatingthe aggregation morphology of mutant hSOD1 proteins in the presence and absenceof the carbazole derivatives using Transmission Electron Microscopy (TEM). In thisstep, samples of the hSOD1 proteins both untreated and treated with the carbazolecompounds, are prepared, typically via negative staining or other suitablepreparation method (100). The TEM allows direct imaging of the aggregate forms,providing visual evidence of how the aggregates form, their shape, structure andwhether the carbazole derivatives have altered or reduced aggregate morphology.
[0088] Further, the method (100) may include a step of determining the sizedistribution of the hSOD1 aggregates under varying conditions by using DynamicLight Scattering (DLS) analysis. In this step, the protein samples (with and withoutcarbazole derivatives) are placed in solution and subjected to DLS measurement toassess how the hydrodynamic size of aggregates changes over time or underdifferent reagent conditions. DLS provides information on the spread of particlesizes, average hydrodynamic radius and degree of polydispersity in the aggregationmixtures.
[0089] The combination of TEM and DLS thus offers a robust evaluation ofaggregation: TEM gives visual and morphological detail of the aggregates, whileDLS gives numerical data on size and distribution. Using both techniques, the effectof carbazole derivatives on preventing or modifying hSOD1 aggregation may beassessed in a comprehensive manner, with both qualitative (morphology) andquantitative (size distribution) aspects covered. This step supports identification ofcompounds that significantly alter aggregation behaviour, thereby aiding thedevelopment of potential therapeutic candidates.
[0090] In some embodiments, the method ( 100) may comprise a step of generationof mutant hSOD1 proteins comprises performing PCR-based site-directedmutagenesis to introduce ALS-associated mutations into a plasmid encoding wildtypehSOD1.
[0091] In some embodiments, the present invention provides a method (100)comprising a step of generation of mutant human superoxide dismutase 1 (hSOD1)proteins. Specifically, the step begins with a plasmid that encodes the wild-typehSOD1 protein. This plasmid serves as the template for introducing diseaseassociatedmutations. The objective of this step is to prepare hSOD1 variantsbearing ALS-associated mutations, so that the therapeutic potential of thecompounds may be studied against these pathological forms.
[0092] In some embodiments, the generation of the mutant hSOD1 proteins isachieved by using PCR-based site-directed mutagenesis. In this approach, primerscarrying the desired mutation(s) are designed and used in a polymerase chainreaction to amplify and modify the wild-type hSOD1 gene. The reaction introducesone or more point mutations corresponding to the known ALS-associated variants,thereby converting the wild-type sequence into a mutant sequence within theplasmid backbone. The method (100) is efficient, reliable and allows precise controlover the mutation site.
[0093] Following the mutagenesis step, the newly synthesized plasmid bearing themutated hSOD1 gene is treated to remove or reduce the parental (wild-type) plasmidbackground, typically by enzymatic digestion of methylated template DNA (forexample DpnI) or comparable means. Thereafter, the mutated plasmid istransformed into a competent host cell (such as E. coli) for propagation andisolation. Sequencing or other suitable molecular-biology verification techniquesare then employed to confirm the presence of the intended mutation and to excludeundesired alterations.
[0094] Thus, this step enables the generation of mutant hSOD1 proteins bearingALS-linked mutations under controlled laboratory conditions. These mutantproteins may subsequently be expressed, purified or used in cellular or biochemicalaggregation assays as part of the wider method (100) of the present invention. Theavailability of well-characterised mutant hSOD1 variants supports the evaluation ofthe inhibitory effects of carbazole derivatives on hSOD1 aggregation and hence aidsthe development of therapeutic agents for ALS.
[0095] In some embodiments, the method (100) may comprise a step of expressingthe mutant human superoxide dismutase 1 (hSOD1) proteins and purifying themusing a nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatography column. Inthis step, the hSOD1 proteins are produced in a suitable host cell such as bacteria,and the recombinant proteins carry a histidine-tag (His-tag) that enables selectivebinding to the Ni-NTA resin. The column is first equilibrated with binding buffer,then the cleared lysate containing the His-tagged hSOD1 is passed through the resin,so that the His-tagged protein binds to immobilised nickel ions. After washing toremove unbound or weakly bound impurities, the target protein is eluted byincreasing imidazole concentration or altering buffer conditions. This provides arelatively pure preparation of hSOD1 suitable for downstream aggregation assays.
[0096] Following purification, the method (100) may further comprises assessingthe inhibitory activity of the synthesized carbazole derivatives by monitoring theaggregation kinetics of the purified hSOD1 proteins with a Thioflavin T (ThT)-based fluorescence assay. In this assay, the purified hSOD1 protein is incubatedunder conditions that promote aggregation, and ThT dye is added because it bindsto amyloid-type fibrils and emits fluorescence when bound. The increase in ThTfluorescence over time corresponds to the formation of aggregated fibrils. For theinhibitory test, the carbazole derivative is included in the reaction to see if thefluorescence increase is delayed or reduced, which would indicate inhibition ofaggregation.
[0097] Further, the combined use of Ni-NTA purification and ThT-based kineticmonitoring thus enables a robust method (100) for preparing the mutant hSOD1proteins and testing how well the carbazole derivatives prevent their aggregation.This approach assists in identifying candidate compounds that may inhibit hSOD1amyloid formation, thereby supporting their further development for diseases suchas Amyotrophic Lateral Sclerosis (ALS). The method (100) is reproducible, allowsquantitative comparison of compound performance, and uses well-establishedlaboratory techniques to provide meaningful biological data on inhibitor efficacy.
[0098] In some embodiments, the aggregation morphology of mutant hSOD1proteins in the presence and absence of carbazole derivatives is evaluated usingtransmission electron microscopy (TEM). Further, the size distribution of SOD1aggregates is determined under varying conditions using Dynamic Light Scattering(DLS) analysis.
[0099] In some embodiments of the present invention, the method (100) maycomprise a step of evaluating the anti-aggregation effects of selected carbazolederivatives in a neuronal cell-based model. The cell-based model used in the method(100) comprises Neuro-2a cells (a mouse neuroblastoma cell line) which have beenstably transfected with a plasmid denoted as pCDH-hSOD1 G85R. In this context,"stably transfected" means that the Neuro-2a cells carry and express the mutanthuman superoxide dismutase 1 protein variant (hSOD1-G85R) as a persistentcharacteristic of the cell line.
[00100] In the model, the Neuro-2a cells bearing the hSOD1 G85R mutationare cultured under appropriate neuronal-cell conditions, and the selected carbazolederivatives are administered to the cultured cells. The cells are then monitored forthe aggregation behaviour of the mutant hSOD1 protein specifically whether thecarbazole derivatives reduce, delay or alter the formation of aggregates comparedto untreated controls. This experimental setup enables assessment of how well agiven carbazole derivative inhibits hSOD1 aggregation in a living cellularenvironment.
[00101] The use of the Neuro-2a / hSOD1 G85R model provides abiologically relevant and reproducible platform for screening and comparing theinhibitory potential of different carbazole derivatives under approximatelyphysiological conditions. This step thereby contributes to identifying leadcompounds for further development and supports the overall objective of providingcarbazole-based compounds capable of addressing aggregation of mutant hSOD1 inneurodegenerative disease contexts.
[00102] In some embodiments, the method (100) may comprise a step ofdetermining the cytotoxic effects of the carbazole derivatives on the neuronal cell10based model. Specifically, the step involves treating the neuronal cells (for examplethe Neuro-2a cells) with selected carbazole derivatives and then assessing how thecompounds affect cell viability. The aim is to ensure that the carbazole derivativesare not harmful to the cells, and to identify safe concentration ranges beforeproceeding to further functional tests.
[00103] In the assay, the treated Neuro-2a cells are subjected to a colourbasedviability test known as the MTT assay. This test is based on the principle thatliving cells may convert a yellow tetrazolium dye (MTT) into a purple formazanproduct via mitochondrial enzymes. After exposure to the carbazole derivatives fora defined period, the MTT dye is added, incubated, then the formazan crystalsformed are solubilised and the absorbance measured. The absorbance value givesan indirect measure of the number of viable cells and their metabolic activity.
[00104] The data obtained from this step enable determination of thepercentage cell viability in treated versus untreated control wells. Any significantdrop in viability indicates cytotoxicity of the derivative, and compounds showingacceptable viability levels may be selected for further studies. This step thereforeensures the safety profile of the carbazole derivatives in the cellular model andsupports their further development in aggregation-inhibition assays and potentialtherapeutic applications.
[00105] In some embodiments, the method (100) comprising a step ofevaluating the protective effect of the carbazole derivatives by assessing their abilityto rescue neuronal cells from cytotoxicity induced by mutant hSOD1 G85R. In thisstep, neuronal cells (for example the previously described Neuro-2a cells) whichexpress the mutant hSOD1 G85R protein are exposed to one or more of thecarbazole derivatives under investigation. The objective is to determine whether thecarbazole derivatives not only reduce protein aggregation, but also improve cellsurvival and protect against the harmful effects caused by the mutant hSOD1protein.
[00106] In the assay, the Neuro-2a cells bearing hSOD1 G85R are culturedunder controlled conditions and treated with selected concentrations of thecarbazole derivatives. After a defined incubation period, the cells are evaluated forviability, morphology and other markers of cytotoxicity (such as cell death,apoptosis or oxidative stress). The protective effect is demonstrated when cellstreated with the carbazole derivatives show greater survival, reduced signs ofdamage, or improved cell health compared to untreated cells exposed to hSOD1G85R alone. The difference between treated and untreated groups thus provides ameasure of the compound's ability to rescue cells from mutant protein-inducedtoxicity.
[00107] This step is especially important from a therapeutic viewpointbecause it links the molecular effect (inhibition of aggregation) to a biologicaloutcome (cell protection). The ability of the carbazole derivatives to rescue neuronalcells from hSOD1 G85R-induced cytotoxicity supports their further developmentas potential lead compounds for neurodegenerative disease treatment. Thus, themethod (100) offers a comprehensive evaluation of both anti-aggregation and cellprotectivefeatures of the carbazole derivatives, contributing to their selection formore advanced studies.
[00108] In some embodiments, the method (100) may further comprise a stepof testing the ability of the carbazole derivatives to moderate reactive oxygenspecies (ROS) generation that is associated with the mutant hSOD1 G85R proteinin Neuro-2a cells. In this step, Neuro-2a cells expressing the hSOD1 G85R mutantprotein are exposed to selected carbazole derivatives under suitable cultureconditions. The aim is to determine whether these compounds may reduce or inhibitthe increased ROS generation which is known to accompany mutant hSOD1expression and contribute to cellular damage.
[00109] During the assay, the Neuro-2a / hSOD1 G85R cells are treated withthe carbazole derivatives, and after a defined incubation period, the level ofintracellular ROS is measured using a suitable ROS-sensitive indicator or dye (forexample H₂DCFDA or similar). The measurement provides a quantitative indicationof how much ROS is being generated in the cells under mutant-protein stress, andhow much the treatment with carbazole derivatives may bring down that ROS level.A reduction in ROS generation in treated cells compared to untreated mutantcontrols indicates that the compound has a protective or moderating effect onoxidative stress.
[00110] This step is important for linking the molecular effect of thecarbazole derivatives (aggregation inhibition) with broader cellular outcomes(oxidative stress reduction). By showing that a compound not only reduces hSOD1aggregation but also moderates ROS generation, the method (100) supports theselection of carbazole derivatives that are more likely to confer beneficial effects ina neurodegenerative context such as ALS. It thus strengthens the case for furtherdevelopment of these derivatives as therapeutic candidates.
[00111] In some embodiments, the method (100) may further comprise a stepof evaluating the ability of the compounds to rescue neuronal cells from hSOD1G85R aggregation-induced apoptosis using both Western blotting and flowcytometry (FACS) analyses. In this step, neuronal cells (for example the previouslymentioned Neuro-2a cells) that express the hSOD1 G85R mutant are treated withselected carbazole derivatives under defined experimental conditions. The purposeis to determine whether the compounds not only reduce aggregation, but also protectthe cells from programmed cell death (apoptosis) triggered by the aggregation ofthe mutant hSOD1 protein.
[00112] In the assay, following treatment and incubation, the cells areharvested and split into two analysis streams. For the Western blotting portion,cellular lysates are prepared and probed with antibodies to key apoptotic markerproteins (for example caspase-3, PARP cleavage, BAX / BCL-2 ratio) to assesswhether the treatment with carbazole derivatives reduces the expression oractivation of these markers compared to untreated, aggregation-induced cells.Meanwhile, in the flow cytometry (FACS) portion, cells are stained with apoptosissensitivedyes such as Annexin-V / Propidium-iodide and analysed to determine thepercentage of early and late apoptotic cells in each treatment group.
[00113] When the carbazole derivatives are effective, one observes a lowerlevel of apoptotic marker proteins on the Western blot and a reduced fraction ofAnnexin-V positive / PI positive cells in the flow cytometry assay compared tountreated mutant-hSOD1 cells. This combined approach therefore provides bothmolecular-level data (via Western blot) and cell-population statistical data (viaFACS) on the protective effect of the compounds. Such evidence supports theselection of compounds that not only inhibit hSOD1 aggregation but also mitigateits downstream harmful effects on neuronal cell survival.
[00114] FIG. 1B illustrates a mechanism (100) of preparation of synthesis ofphenylchloroformate, DCM, TEA, RT for 6h, Hydrazine hydrate, 1,4-dioxane,reflux for 8h and 4-Substituted phenyl isocyanate / isothiocyanate, Acetonitrile,reflux, according to an embodiment of the present invention.
[00115] In some embodiments, the synthesis of the carbazole-basedderivatives (compounds 4-19) for potential treatment of amyotrophic lateralsclerosis (ALS) is carried out through a three-step reaction sequence, as illustratedin FIG. 1A. The process begins with commercially available carbazole, whichserves as the core structural scaffold due to its established biological activity andability to interact with neuroprotective targets. In the first step, carbazole reacts withphenyl chloroformate, resulting in the formation of a carbamate intermediate,specifically (9-ethyl-9H-carbazol-3-yl)-carbamic acid phenyl ester (compound 2).Further, this reaction introduces a reactive carbamate linkage, which provides asuitable functional handle for further derivatization.
[00116] Following this, the phenyl ester derivative (compound 2) undergoesreflux with hydrazine hydrate, leading to the formation of the key intermediate acidhydrazide (compound 3). Further, this transformation replaces the phenoxy groupwith a hydrazide moiety, enhancing the molecule's potential for further couplingreactions and biological activity modulation. The hydrazide functionality alsoserves as a versatile intermediate for the introduction of urea or thiourea linkages,which are commonly associated with hydrogen bonding and enhancedpharmacological properties.
[00117] Finally, in the acid hydrazide (compound 3) is reacted with various4-substituted phenyl isocyanates or isothiocyanates, yielding the final series oftarget carbazole derivatives (compounds 4-19). Further, this coupling stepintroduces structural diversity into the final molecules, allowing systematicmodification of the substituents (R and X groups) to fine-tune their physicochemicaland biological characteristics. The resulting carbazole derivatives are designed toexplore their neuroprotective potential and therapeutic relevance in ALS bytargeting oxidative stress, excitotoxicity, and mitochondrial dysfunction keypathological mechanisms of the disease.
[00118] Further, the synthesized compounds are thoroughly characterizedusing spectroscopic and analytical methods, including ¹H NMR, ¹³C NMR, massspectrometry, and elemental analysis, confirming the purity and structural integrityof the final products. Further, the synthetic approach provides a straightforward andefficient route to a diverse library of carbazole-based derivatives, facilitating thedevelopment of novel molecules for ALS therapy.
[00119] FIG. 2A illustrates a graphical representation (200) of 1H and 13CNMR of compound 12 (SG-9), according to an embodiment of the presentinvention. FIG. 2B illustrates another graphical representation (200) of 1H and 13CNMR of compound 12 (SG-9), according to an embodiment of the presentinvention. FIG. 2C illustrates another graphical representation (200) of Mass spectraand HPLC chromatogram of compound 12 (SG-9), according to an embodiment ofthe present invention. FIG. 2D illustrates another graphical representation (200) ofMass spectra and HPLC chromatogram of compound 12 (SG-9), according to anembodiment of the present invention. FIG. 3A illustrates a graphical representation(300) of 1H and 13C NMR of compound 13 (SG-10), according to an embodimentof the present invention. FIG. 3B illustrates a graphical representation (300) of 1Hand 13C NMR of compound 13 (SG -10), according to an embodiment of the presentinvention. FIG. 3C illustrates a graphical representation (300) of Mass spectra andHPLC chromatogram of compound 13 (SG-10), according to an embodiment of thepresent invention. FIG. 3D illustrates a graphical representation (300) of Massspectra and HPLC chromatogram of compound 13 (SG-10), according to anembodiment of the present invention.
[00120] In some embodiments, the characterisation is performed. Further, theobtained data is as follows:
[00121] Phenyl (9-ethyl-9H-carbazol-3-yl)carbamate (2)White solid; yield 88%; mp 182-184 °C. 1H-NMR (400 MHz, DMSO-d6) δ 10.13(s, 1H), 8.25 (s, 1H), 8.01 (d, J=7.7 Hz, 1H), 7.52 (dd, J=22.1, 8.8 Hz, 3H), 7.41 (t,J=8.0 Hz, 3H), 7.21-7.25 (m, 3H), 7.13 (t, J=7.5 Hz, 1H), 4.38 (q, J=7.1 Hz, 2H),1.27 (t, J=7.1 Hz, 3H); LC-MS: m / z; 331 (M+1)
[00122] N-(9-ethyl-9H-carbazol-3-yl)hydrazinecarboxamide (3)White solid; yield 86%; mp 202-204 °C. 1H-NMR (400 MHz, DMSO-d6) δ 8.56(s, 1H), 8.22 (s, 1H), 7.99 (d, J=7.6 Hz, 1H), 7.36-7.52 (m, 4H), 7.27 (s, 1H), 7.11(t, J=7.8 Hz, 1H), 4.35 (q, J=7.1 Hz, 4H), 1.25 (t, J=7.1 Hz, 3H); LC-MS: m / z; 269(M+1)
[00123] 3-(9-ethyl-9H-carbazol-3-yl)-1-[(phenylcarbamoyl)amino]urea(4)White solid; yield 72%; mp: ;1H-NMR (400 MHz, DMSO-D6) δ 8.73 (d, J = 14.7Hz, 2H), 8.20 (s, 1H), 7.91-7.99 (m, 3H), 7.35-7.51 (m, 6H), 7.21 (d, J = 15.6 Hz,2H), 7.10 (s, 1H), 6.90 (t, J = 7.6 Hz, 1H), 4.35 (q, J = 7.2 Hz, 2H), 1.24 (t, J = 7.1Hz, 3H); 13C NMR (100 MHz, DMSO-d6): δ 157.10, 156.68, 140.46, 140.29,136.21, 132.08, 129.15, 126.14, 122.58, 122.50, 122.34, 120.66, 119.56, 119.00,118.89, 111.42, 109.59, 109.41, 37.46, 14.23; LC-MS: m / z: 388.17 (M+1); Anal.Calcd for C22H21N5O2: C (68.20%), H (5.46%), N (18.08%); Found: C (68.16%),H (5.82%), N (17.64%).
[00124] 3-(9-ethyl-9H-carbazol-3-yl)-1-{[(4fluorophenyl)c arbamoyl]amino}urea (5)White solid; yield 70%; mp: ;1H-NMR (400 MHz, DMSO-D6) δ 8.83 (s, 1H), 8.71(s, 1H), 8.20 (s, 1H), 7.92-7.99 (m, 3H), 7.76-7.74 (0H), 7.44-7.51 (m, 5H), 7.37 (t,J = 7.6 Hz, 1H), 7.03-7.12 (m, 3H), 4.34 (q, J = 7.0 Hz, 2H), 1.24 (t, J = 7.1 Hz,3H); 13C NMR (100 MHz, DMSO-d6): δ 157.06, 156.81, 140.46, 136.68, 136.21,132.07, 126.14, 122.58, 122.48, 120.65, 118.88, 115.70, 115.47, 111.43, 109.59,109.40, 37.45, 14.23; LC-MS: m / z: 406.16 (M+1); Anal. Calcd for C22H20FN5O2:C (65.18%), H (4.97%), F (4.69%), N (17.27%); Found: C (65.23%), H (5.10%), N(17.47%).
[00125] 3-(9-ethyl-9H-carbazol-3-yl)-1-{[(4-chlorophenyl)carbamoyl]amino}urea (6)White solid; yield 78%; mp: ; 1H-NMR (400 MHz, DMSO-D6) δ 8.93 (s, 1H), 8.72(s, 1H), 8.20 (s, 1H), 7.98 (dd, J = 26.8, 19.0 Hz, 3H), 7.43-7.54 (m, 5H), 7.36 (t, J= 7.3 Hz, 1H), 7.25 (d, J = 8.7 Hz, 2H), 7.10 (t, J = 7.3 Hz, 1H), 4.34 (q, J = 7.0 Hz,2H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, DMSO-d6): δ 157.02, 156.62,140.46, 139.37, 136.22, 132.05, 128.96, 126.14, 125.86, 122.58, 122.48, 120.66,120.60, 118.89, 109.60, 109.40, 37.46, 14.23; LC-MS: m / z: 422.13 (M+1); Anal.Calcd for C22H20ClN5O2: C (62.63%), H (4.78%), Cl (8.40%), N (16.60%); Found:C (62.72%), H (4.86%), N (16.18%).
[00126] 3-(9-ethyl-9H-carbazol-3-yl)-1-{[(4-nitrophenyl)carbamoyl]amino}urea (7)White solid; yield 75%; mp: ; 1H-NMR (400 MHz, DMSO-D6) δ 9.53 (s, 1H), 8.77(s, 1H), 8.12-8.32 (m, 4H), 7.99 (d, J = 12.8 Hz, 2H), 7.76 (s, 2H), 7.35-7.51 (m,4H), 7.09 (t, J = 7.3 Hz, 1H), 4.32-4.37 (m, 2H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR(100 MHz, DMSO-d6): δ 150.77, 147.11, 144.25, 141.58, 140.46, 136.25, 131.98,126.16, 125.50, 122.57, 122.48, 120.66, 118.90, 118.37, 109.60, 109.42, 106.92,106.70, 37.45, 14.23; LC-MS: m / z: 433.16 (M+1); Anal. Calcd for C22H20N6O4: C(61.10%), H (4.66%), N (19.43%); Found: C (61.40%), H (4.70%), N (19%).
[00127] 3-(9-ethyl-9H-carbazol-3-yl)-1-{[(4-methoxyphenyl)carbamoyl]amino}urea (8)White solid; yield 80%; mp: ; 1H-NMR (400 MHz, DMSO-D6) δ 8.69 (s, 1H), 8.59(s, 1H), 8.20 (s, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.87 (d, J = 6.4 Hz, 2H), 7.46-7.52(m, 3H), 7.35-7.38 (m, 3H), 7.10 (t, J = 7.3 Hz, 1H), 6.79 (d, J = 9.2 Hz, 2H), 4.35(q, J = 7.0 Hz, 2H), 3.65 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz,DMSO-d6): δ 157.11, 156.87, 154.93, 140.46, 140.44, 136.19, 136.17, 133.34,133.31, 132.11, 126.14, 122.58, 122.48, 120.79, 120.66, 118.88, 114.32, 109.60,109.40, 55.66, 37.46, 14.25, 14.23; LC-MS: m / z: 418.18 (M+1); Anal. Calcd forC23H23N5O3: C (66.17%), H (5.55%), N (16.78%); Found: C (65.97%), H (5.63%),N (16.20%).
[00128] 3-(9-ethyl-9H-carbazol-3-yl)-1-({[4(trifluoromethoxy)phenyl]carbamoyl}amino)urea (9)White solid; yield 79%; mp: ; 1H-NMR (400 MHz, DMSO-D6) δ 9.00 (s, 1H), 8.72(s, 1H), 8.19 (s, 1H), 7.93-8.06 (m, 3H), 7.35-7.60 (m, 6H), 7.22 (d, J = 8.2 Hz,2H), 7.10 (t, J = 7.3 Hz, 1H), 4.35 (q, J = 7.0 Hz, 2H), 1.24 (t, J = 7.1 Hz, 3H); 13CNMR (100 MHz, DMSO-d6): δ 157.01, 140.46, 140.44, 139.67, 136.22, 132.06,126.15, 122.57, 122.48, 122.03, 120.66, 120.26, 118.89, 109.60, 109.40, 37.46,14.22; LC-MS: m / z: 472.15 (M+1); Anal. Calcd for C23H20F3N5O3: C (58.60%), H(4.28%), N (14.86%); Found: C (58.64%), H (4.05%), N (16.10%).
[00129] 3-(9-ethyl-9H-carbazol-3-yl)-1-[(benzylcarbamoyl)amino]urea(10)White solid; yield 83%; mp: ; 1H-NMR (400 MHz, DMSO-D6) δ 8.66 (s, 1H), 8.24(s, 1H), 7.85-8.04 (m, 3H), 7.09-7.56 (m, 10H), 4.27-4.40 (m, 4H), 1.27-1.30 (m,3H); 13C NMR (100 MHz, DMSO-d6): δ 159.44, 157.04, 141.16, 140.45, 136.17,132.11, 128.62, 127.56, 127.54, 127.02, 126.12, 122.59, 122.57, 122.46, 120.63,119.58, 118.90, 118.87, 111.40, 109.61, 109.40, 109.38, 43.21, 37.45, 14.24; LC-MS: m / z: 402.19 (M+1); Anal. Calcd for C23H23N5O2: C (68.81%), H (5.77%), N(17.44%); Found: C (68.22%), H (5.78%), N (19.06%).
[00130] 3-(9-ethyl-9H-carbazol-3-yl)-1-{[(2-phenylethyl)carbamoyl]amino}urea (11)White solid; yield 82%; mp: ; 1H-NMR (400 MHz, DMSO-D6) δ 8.56 (s, 1H), 8.20(s, 1H), 7.98 (s, 1H), 7.14-7.50 (m, 12H), 5.81 (s, 1H), 4.34 (q, J = 6.9 Hz, 2H),3.12-3.18 (m, 2H), 2.60 (t, J = 7.1 Hz, 2H), 1.23 (t, J = 6.9 Hz, 3H); 13C NMR (100MHz, DMSO-d6): δ 140.43, 140.32, 129.20, 128.81, 126.48, 122.61, 118.79,110.82, 109.55, 109.39, 41.43, 36.72, 14.23; LC-MS: m / z: 416.16 (M+1); Anal.Calcd for C24H25N5O2: C (69.38%), H (6.07%), N (16.86%); Found: C (70.40%),H (5.97%), N (18.09%).
[00131] 3-(9-ethyl-9H-carbazol-3-yl)-1-[(phenylcarbamothioyl)amino]urea (12) (SG-9)White solid; yield 85%; mp: ; 1H-NMR (400 MHz, DMSO-D6) δ 9.81 (s, 1H), 9.47(s, 1H), 8.76 (s, 1H), 8.19 (d, J = 11.0 Hz, 2H), 8.00 (d, J = 7.8 Hz, 1H), 7.36-7.51(m, 8H), 7.10 (q, J = 6.9 Hz, 2H), 4.35 (q, J = 7.0 Hz, 2H), 1.24 (t, J = 7.1 Hz, 3H);13C NMR (100 MHz, DMSO-d6): δ 155.99, 140.47, 139.77, 136.25, 131.94,129.50, 128.55, 126.20, 122.55, 122.51, 121.54, 120.69, 118.92, 111.34, 109.62,109.50, 37.47, 14.25; LC-MS: m / z: 404.15 (M+1); Anal. Calcd for C22H21N5OS:C (65.49%), H (5.25%), N (17.36%), S (7.95%); Found: C (66.37%), H (4.82%), N(18.67%), S (8.30%); HPLC purity: 99.58%.
[00132] 3-(9-ethyl-9H-carbazol-3-yl)-1-{[(4-fluorophenyl)carbamothioyl]amino}urea (13) (SG-10)White solid; yield 75%; mp: ; 1H-NMR (400 MHz, DMSO-D6) δ 9.83 (s, 1H), 9.49(s, 1H), 8.74 (s, 1H), 8.19 (d, J = 12.4 Hz, 2H), 8.00 (d, J = 7.3 Hz, 1H), 7.36-7.53(m, 7H), 7.09-7.14 (m, 3H), 4.36 (q, J = 7.2 Hz, 2H), 1.25 (t, J = 7.1 Hz, 3H); 13CNMR (100 MHz, DMSO-d6): δ 207.10, 192.12, 155.96, 140.45, 140.43, 136.23,131.94, 131.92, 126.21, 126.18, 122.52, 122.48, 120.68, 118.93, 109.63, 109.48,31.24, 14.25; LC-MS: m / z: 422.14 (M+1); Anal. Calcd for C22H20FN5OS: C(62.69%), H (4.78%), F (4.51%), N (16.62%), S (7.61%); Found: C (62.57%), H(4.33%), N (17.99%), S (7.80%); HPLC purity: 98.93%.
[00133] SG-11 3-(9-ethyl-9H-carbazol-3-yl)-1-{[(4chlorophenyl)c arbamothioyl]amino}urea (14)White solid; yield 73%; mp: ; 1H-NMR (400 MHz, DMSO-D6) δ 9.88 (s, 1H), 9.56(s, 1H), 8.76 (s, 1H), 8.19 (d, J = 11.4 Hz, 2H), 8.00 (d, J = 6.0 Hz, 1H), 7.28-7.55(m, 9H), 7.10 (d, J = 14.7 Hz, 1H), 4.34 (q, J = 7.2 Hz, 2H), 1.23 (t, J = 6.9 Hz, 3H);13C NMR (100 MHz, DMSO-d6): δ 163.20, 155.95, 140.47, 138.82, 136.27,131.91, 128.43, 126.21, 122.55, 122.51, 120.68, 119.47, 118.93, 111.38, 109.63,109.49, 37.48, 14.25; LC-MS: m / z: 438.11 (M+1); Anal. Calcd for C22H20ClN5OS:C (60.34%), H (4.60%), N (15.99%), S (7.32%); Found: C (60.60%), H (4.46%), N(15.24%), S (7.15%).
[00134] 3-(9-ethyl-9H-carbazol-3-yl)-1-{[(4-nitrophenyl)carbamothioyl]amino}urea (15)White solid; yield 79%; mp: ; 1H-NMR (400 MHz, DMSO-D6) δ 9.53 (s, 1H), 8.77(s, 1H), 8.12-8.32 (m, 4H), 7.99 (d, J = 12.8 Hz, 2H), 7.76 (s, 2H), 7.35-7.51 (m,4H), 7.09 (t, J = 7.3 Hz, 1H), 4.32-4.37 (m, 2H), 1.23 (t, J = 7.1 Hz, 3H);13C NMR(100 MHz, DMSO-d6): δ 155.85, 140.47, 136.31, 131.81, 122.55, 122.51, 120.68,118.93, 109.63, 109.49, 37.48, 14.24; LC-MS: m / z: 449.13 (M+1); Anal. Calcd forC22H20N6O3S: C (58.92%), H (4.49%), N (18.74%), S (7.15%); Found: C (58.34%),H (4.71%), N (17.78%), S (7.10%).
[00135] 3-(9-ethyl-9H-carbazol-3-yl)-1-{[(4-methoxyphenyl)carbamothioyl]amino}urea (16)White solid; yield 80%; mp: ; 1H-NMR (400 MHz, DMSO-D6) δ 8.66 (s, 1H), 8.56(s, 1H), 8.17 (s, 1H), 7.83-7.99 (m, 3H), 7.32-7.49 (m, 6H), 7.07 (d, J = 15.1 Hz,1H), 6.76 (d, J = 9.2 Hz, 2H), 4.31 (dd, J = 21.8, 7.6 Hz, 2H), 3.62 (s, 3H), 1.21 (t,J = 7.1 Hz, 3H); 13C NMR (100 MHz, DMSO-d6): δ 157.12, 156.88, 154.93,140.45, 136.18, 133.33, 132.10, 126.14, 122.57, 122.48, 120.78, 120.66, 119.54,118.88, 114.31, 109.60, 109.40, 55.65, 37.46, 14.24; LC-MS: m / z: 434.18 (M+1);Anal. Calcd for C23H23N5O2S: C (63.72%), H (5.35%), N (16.15%), S (7.40%);Found: C (66.11%), H (5.65%), N (16.41%), S (7.19%).
[00136] 3-(9-ethyl-9H-carbazol-3-yl)-1-({[4(trifluoromethoxy)phenyl]carbamothioyl}amino)urea (17)White solid; yield 74%; mp: ; 1H-NMR (400 MHz, DMSO-D6) δ 9.96-9.88 (1H),9.60-9.47 (1H), 8.80-8.65 (1H), 8.25-8.14 (2H), 8.00-7.90 (1H), 7.67-7.17 (8H),7.11-7.01 (1H), 4.41-4.26 (2H), 1.27-1.15 (3H); 13C NMR (100 MHz, DMSO-d6):δ 155.95, 140.46, 139.04, 136.27, 131.89, 126.19, 122.54, 122.50, 121.23, 120.68,119.47, 118.93, 111.37, 109.62, 109.48, 37.47, 14.24; LC-MS: m / z: 488.13 (M+1);Anal. Calcd for C23H20F3N5O2S: C (56.67%), H (4.14%), N (14.37%), S (6.58%);Found: C (56.00%), H (3.98%), N (15.79%), S (6.60%).
[00137] 3-(9-ethyl-9H-carbazol-3-yl)-1-[(benzylcarbamothioyl)amino]urea (18)White solid; yield 69%; mp; 1H-NMR (400 MHz, DMSO-D6) δ 8.66 (s, 1H), 8.24(s, 1H), 7.85-8.04 (m, 3H), 7.09-7.56 (m, 10H), 4.27-4.40 (m, 4H), 1.27-1.30 (m,3H); 13C NMR (100 MHz, DMSO-d6): δ 155.97, 140.46, 139.97, 136.25, 131.90,128.55, 127.71, 127.11, 126.19, 122.53, 122.48, 120.65, 119.49, 118.93, 111.39,109.63, 109.47, 47.22, 37.47, 14.25; LC-MS: m / z: 418.16 (M+1); Anal. Calcd forC23H23N5OS: C (66.16%), H (5.55%), N (16.77%), O (3.83%), S (7.68%); Found:C (65.82%), H (5.38%), N (16.39%), S (7.72%).
[00138] 3-(9-ethyl-9H-carbazol-3-yl)-1-{[(2-phenylethyl)carbamothioyl]amino}urea (19)White solid; yield 75%; mp: ; 1H-NMR (400 MHz, DMSO-D6) δ 9.81 (s, 1H), 9.47(s, 1H), 8.76 (s, 1H), 8.19 (d, J = 11.0 Hz, 2H), 8.00 (d, J = 7.8 Hz, 1H), 7.36-7.51(m, 8H), 7.10 (q, J = 6.9 Hz, 2H), 4.35 (q, J = 7.0 Hz, 2H), 1.24 (t, J = 7.1 Hz, 3H);13C NMR (100 MHz, DMSO-d6): δ 156.01, 140.46, 139.93, 136.26, 131.87,129.22, 129.20, 129.17, 128.90, 126.60, 126.19, 122.54, 122.48, 120.66, 119.50,118.93, 111.41, 109.63, 109.46, 45.73, 37.47, 35.39, 14.25; LC-MS: m / z: 432.16(M+1); Anal. Calcd for C24H25N5OS: C (66.80%), H (5.84%), N (16.23%), O(3.71%), S (7.43%); Found: C (66.49%), H (5.91%), N (16.49%), S (7.43%).
[00139] FIG. 4 illustrates pictorial representation (400) of (a) restriction mapof pET15b SOD1 plasmid, (b) restriction digestion of pET15b SOD1 plasmid,double digestion with XbaI and EcoRI yields a pop out of 867bp while double cutwith EcoRV yields two bands of 1.8kb and 4.3kb and (c) comparison between thesequenced data of WT SOD1 plasmid and SOD1 mRNA sequence reveals 100%sequence similarity, according to an embodiment of the present invention.
[00140] In some embodiments, the generation of mutant SOD1 plasmids iscarried out. To confirm the presence of the SOD1 sequence in the pET15b plasmid,restriction digestion is performed. Double digestion with XbaI and EcoRI yields apop out of 867bp while double cut with EcoRV yields two bands of 1.8kb and 4.3kb(FIG. 4b). The plasmid is then sent for Single Pass sequencing and the results show100% identity in the sequence with SOD1 mRNA sequence as illustrated in FIG.4c.
[00141] FIG. 5 illustrates a pictorial representation (500) of (a) PCR reactionat 72 °C annealing temperature for A4V mutant and at 65 °C for G85R and G93Amutant with 1ng and 10ng template, and comparison between the sequenced data ofSOD1 mRNA sequence with plasmid reveals a single base change of (b) C to T forA4V, (c) G to C for G85R and (d) G to C for G93A mutant respectively, accordingto an embodiment of the present invention.
[00142] In some embodiments, the PCR-based site-directed mutagenesis isperformed. Further, the PCR-based site-directed mutagenesis is performed togenerate three mutant forms of SOD1 protein (A4V, G85R and G93A) that causefamilial ALS. The A4V mutation lies in the dimer interface of SOD1 and affects itsdimerization, G85R is a metal binding region mutation and the G93A mutation is inone of the β-strands. Annealing temperatures are standardised by performinggradient PCR reactions and finally, the PCR reactions are performed at 72 °C annealing temperature (2-step PCR) for the A4V mutant and 65 °C annealingtemperature for mutants G85R and G93A (FIG. 5a). E. coli is transformed using themutated plasmids and isolated plasmids from the colonies are then sent forsequencing. Sequencing results display the intended base changes from C to T forA4V (FIG. 5b), G to C for G85R (FIG. 5c) and G to C for G93A mutant.
[00143] FIG. 6A illustrates a pictorial representation (600) of IPTGconcentration gradient at 20º C for 19hrs. SOD1 induction is seen as a 17kDa bandat all the concentrations, according to an embodiment of the present invention. FIG.6B illustrates another pictorial representation (600) of the SDS-PAGE of all thefractions during hSOD1 A4V mutant protein purification, according to anembodiment of the present invention. FIG. 6C illustrates another pictorialrepresentation (600) of the SDS-PAGE of all the fractions during hSOD1 G85Rmutant protein purification, according to an embodiment of the present invention.FIG. 6D illustrates another pictorial representation (600) of the SDS-PAGE of allthe fractions during hSOD1 G93A mutant protein purification, according to anembodiment of the present invention. FIG. 6E illustrates another pictorialrepresentation (600) of the Western blot with hSOD1 antibody confirm purifiedproteins as mutant SOD1 proteins, according to an embodiment of the presentinvention.
[00144] In some embodiments, the method (100) includes the purification ofmutant SOD1 proteins. The purification of the mutant SOD1 proteins (A4V, G85Rand G93A) involves inducing expression of the target protein, extracting proteinsby sonication, and performing fractional ammonium sulphate precipitation followedby Ni-NTA chromatography. Cultures are induced at various temperatures andIPTG concentrations to optimise protein expression. Protein yield is lower at 37 °C,whereas at 20 °C an optimal yield is obtained when induced with 0.1 mM IPTG. AnSDS gel of the purification steps for SOD1 A4V shows a band at 17 kDa in theinduced sample lane. Ammonium sulphate precipitation helps remove non-specificproteins, though a small amount of SOD1 A4V protein is also lost. The flow-throughlane after binding with Ni-NTA beads shows complete binding of SOD1 A4V to thebeads. Some of the SOD1 A4V protein is lost in the wash steps but the final elutionshows no non-specific protein. All the elutes are then concentrated using an Amiconfilter and the protein concentration is measured by the Bradford assay using BSA asstandard. Similar results are obtained for SOD1 G85R and SOD1 G93A proteins.The concentrated proteins are more than 95% pure and are confirmed as SOD1proteins by western blotting using a human SOD1 antibody.
[00145] FIG. 7A illustrates a tabular representation (700) of the depictingpercentage inhibition potencies of compounds (4-19) at 50μM concentration againstaggregation of mutant SOD1 protein (A4V, G85R and G93A), according to anembodiment of the present invention. FIG. 7B illustrates a graphical representation(700) of the mean fluorescence intensities of ThT for mutant SOD1 proteins aloneand with co-incubation of SG-9 and SG-10, according to an embodiment of thepresent invention.
[00146] In some embodiments, various mutant forms of SOD1 proteins areknown to form amyloid-like aggregates under different physiological conditions.The TCEP-treated mutant SOD1 A4V, G85R and G93A (50 μM) are incubatedalone or together with the compounds (50 μM) for 24 hours at 37 °C with agitationto test how well the compounds, inhibit the aggregation. The unaggregated controlsample is the mutant protein stored at 4 °C without agitation.
[00147] The degree of aggregate formation is determined using aThioflavin T (ThT) fluorescence assay. A decrease in ThT fluorescence is seen inall compound-treated groups compared to the mutant SOD1-only groups for allthree mutants, indicating a reduction in aggregate formation as illustrated in FIG.7B. The percentage inhibition potencies of all the synthesized derivatives againstthe mutant SOD1 proteins are summarised in FIG. 7A. Most of the compoundsinhibit aggregate formation by about 50% at 50 μM concentration.
[00148] As positive controls, curcumin and riluzole are also tested: riluzoleshows no anti-aggregation potency, whereas curcumin does inhibit aggregation ofthe mutant SOD1 proteins. Among the derivatives, SG-9 and SG-10 show thehighest anti-aggregation potentials, with inhibitory potencies of 71.31% and 76.18%against SOD1 A4V, 74.85% and 76.79% against SOD1 G85R, and 88.32% and80.67% against SOD1 G93A, respectively. Furthermore, when the compoundsthemselves are tested alone, they do not show any significant ThT fluorescenceresponse, indicating that they do not bind ThT or enhance its fluorescence.
[00149] FIG. 8 illustrates a pictorial representation (800) of transmissionelectron micrographs displaying a reduction in the mutant SOD1 proteinaggregation in the treated groups in comparison with the aggregated sample,according to an embodiment of the present invention.
[00150] In some embodiments, the compounds SG-9, SG-10 and curcumininhibits the formation of amyloid-like aggregates, as monitored by transmissionelectron microscopy (TEM). The ability of compounds SG-9, SG-10 and curcuminto inhibit the aggregation of mutant SOD1 (A4V, G85R and G93A) proteins isfurther evaluated by TEM.
[00151] As shown in FIG. 8, when the mutant SOD1 proteins are incubatedat 4 °C for 24 h, no fibrils or aggregates are observed in the unaggregated sample.In contrast, when the proteins are incubated at 37 °C for 24 h, mature and denseaggregates formed for all three mutant proteins. Upon co-incubation with SG-9,SG-10 or curcumin at a concentration of 50 μM, the formation of aggregates isinhibited. Further, only a few slender fibrils are seen, with no mature denseaggregates.
[00152] In some embodiments, both SG-9 and SG-10 showed a greaterreduction in aggregate formation than curcumin. The inhibitory potencies of thecompounds align with the results of the Thioflavin T (ThT) binding assay,confirming that the compounds are effective at inhibiting mutant SOD1 aggregation.
[00153] FIG. 9A illustrates a graphical representation (900) of sizedistribution plots of untreated and treated samples of SOD1 A4V mutant protein,according to an embodiment of the present invention. FIG. 9B illustrates a graphicalrepresentation (900) of size distribution plots of untreated and treated samples ofSOD1 G85R mutant protein, according to an embodiment of the present invention.FIG. 9C illustrates a graphical representation (900) of size distribution plots ofuntreated and treated samples of SOD1 G93A mutant protein, according to anembodiment of the present invention.
[00154] In some embodiments, comparatively smaller prefibrillar aggregatesare formed in the SG-9 and SG-10 treated samples. To determine the size of theaggregates in the TCEP-treated mutant hSOD1 proteins (A4V, G85R and G93A)with and without the compounds, the size-distribution profiles are assessed usingDynamic Light Scattering (DLS) (a technique used to determine the size distributionof particles in suspension or polymers in solution).
[00155] For the SOD1 A4V mutant: when incubated at 4 °C for 24 h theparticle size is around 14.19 nm; upon incubation at 37 °C for 24 h it increases to154.4 nm. Co-incubation with SG-9, SG-10 and curcumin at 50 μM reduces the sizeprofiles to 44.57 nm, 27.71 nm and 52.15 nm respectively (FIG. 9A).
[00156] Similarly, for SOD1 G85R: incubation at 4 °C for 24 h gives a sizeof about 8.05 nm; at 37 °C for 24 h it increases to 151.1 nm. With SG-9, SG-10 andcurcumin the size is reduced to 36.31 nm, 26.44 nm and 40.17 nm respectively(Figure 9B). For SOD1 G93A: size at 4 °C for 24 h is 11.08 nm; at 37 °C for 24 hthe average size is 84.38 nm. Co-incubation with SG-9, SG-10 and curcuminreduces this to 25.21 nm, 21.67 nm and 31.68 nm respectively (Figure 9C). SG-10proved to be the most effective in reducing the size of all three mutant hSOD1proteins, thereby preventing aggregation most effectively.
[00157] FIG. 10 illustrates a graphical representation (1000) of percentageviabilities at various concentrations of tested compounds SG-9 and SG-10,according to an embodiment of the present invention.
[00158] In some embodiments, it is observed that the compounds SG-9 andSG-10 exhibited no significant cytotoxicity in N2a cells. In the assay, theNeuroblastoma cell line N2a, which overexpresses hSOD1 G85R protein, is used toevaluate the cytotoxicity of SG-9, SG-10 and curcumin by means of the MTT(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reduction assay.All three compounds are tested at concentrations of 1, 5, 10 and 25 μM for a durationof 48 h.
[00159] The cells treated with DMSO (at the tested concentration) displayedno significant change in cell viability, serving as a vehicle control. SG-9, SG-10 andcurcumin did not show any cytotoxic effect up to the concentration of 10 μM.However, at 25 μM there is a small amount of cytotoxicity associated with thecompounds (as illustrated in FIG. 10). These results confirm that SG-9, SG-10 andcurcumin may be used for further cellular assays since they do not display markedtoxicity under the tested conditions.
[00160] FIG. 11A illustrates a graphical representation (1100) of Percentagecell viability upon treatment of MG-132 with and without the pre-treatment ofdifferent concentrations of SG-9 and SG-10, according to an embodiment of thepresent invention. FIG. 11B illustrates a pictorial representation (1100) of Phasecontrast microscopy pictures also depict similar conclusions, according to anembodiment of the present invention.
[00161] In some embodiments, it is observed that the compounds SG-9 andSG-10 exhibited no significant cytotoxicity in N2a cells. In the assay, theNeuroblastoma cell line N2a, which overexpresses hSOD1 G85R protein, is used toevaluate the cytotoxicity of SG-9, SG-10 and curcumin by means of the MTT(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reduction assay.All three compounds are tested at concentrations of 1, 5, 10 and 25 μM for a durationof 48 h. The cells treated with DMSO (at the tested concentration) displayed nosignificant change in cell viability, serving as a vehicle control. SG-9, SG-10 andcurcumin did not show any cytotoxic effect up to the concentration of 10 μM.However, at 25 μM there is a small amount of cytotoxicity associated with thecompounds (as illustrated in FIG. 10). These results confirm that SG-9, SG-10 andcurcumin may be used for further cellular assays since they do not display markedtoxicity under the tested conditions.
[00162] FIG. 12 illustrates a graphical representation (1200) of pre-treatmentwith SG-9 and SG-10 before the treatment of MG-132 protects cells from SOD1G85R aggregation-associated toxicity, according to an embodiment of the presentinvention.
[00163] In some embodiments, the treatment with SG-9 and SG-10 protectsN2a cells from oxidative stress. One of the proposed mechanisms ofneurodegeneration in Amyotrophic Lateral Sclerosis (ALS) is the generation ofreactive oxygen species (ROS). Aggregation of mutant hSOD1 protein is known tocause mitochondrial dysfunction and oxidative stress. To evaluate this, cells aretreated with MG-132 (a proteasome‐clearance inhibitor) which is known to inhibitthe clearance of aggregated proteins in cells. The ROS levels are increased in thetransfected N2a cells upon treatment with MG-132 compared to untreated cells.Pre-treatment of the cells with SG-9, SG-10 and curcumin before MG-132 treatmentsignificantly reduced the generation of ROS compared to the group without anypre-treatment. Among these, SG-10 showed a greater reduction in ROS generationthan the other pre-treatments.
[00164] FIG. 13 illustrates a graphical representation (1300) of pre-treatmentwith SG-9 and SG-10 before the treatment of MG-132 protects cells from SOD1G85R aggregation-associated toxicity, according to an embodiment of the presentinvention.
[00165] In some embodiments, treatment with SG-9 and SG-10 rescues N2acells from apoptosis induced by aggregation of hSOD1 G85R. Further, it is knownthat mitochondria-mediated apoptosis is linked to motor-neuron degeneration inALS, and that mutant SOD1 proteins can bind anti-apoptotic factors such as Bcl-2,thereby promoting cell death.
[00166] In the experiment, transfected N2a cells expressing hSOD1 G85Rare treated with MG-132, which inhibits proteasomal clearance and therebyenhances aggregation of hSOD1. As expected, MG-132 treatment triggeredapoptosis associated with hSOD1 G85R aggregation in the cells. Pre-treatment withSG-9, SG-10 or curcumin (all shown to have anti-aggregation activity) markedlyreduced the apoptosis compared to cells that received no pre-treatment (FIG. 13A).
[00167] Moreover, treatment with MG-132 led to a reduction in the levels ofanti-apoptotic proteins such as Bcl-2 and XIAP. However, when the cells arepre-treated with SG-9, SG-10 or curcumin, the expression of these anti-apoptoticproteins is restored (FIG. 13B). This result indicates that SG-9 and SG-10 not onlyinhibit aggregation of mutant SOD1, but also protect neuronal cells fromdownstream apoptosis by maintaining key survival protein levels.
[00168] It has thus been observed that the method (100) for the synthesis ofcarbazole derivatives for treatment of amyotrophic lateral sclerosis, as described, isversatile and may undergo numerous modifications and variants, all of which areencompassed within the same inventive concept. The steps, solvent compositions,durations, and concentrations can be adjusted or substituted with technicallyequivalent procedures without departing from the core methodology. In practice,the quantities, ratios, temperatures, and equipment used can vary according toexperimental or technical requirements. Therefore, the scope of protection of theinvention is defined by the appended claims and is not limited to the specificembodiments described herein.
Claims
1. A method (100) for the synthesis of carbazole derivatives for treatment of amyotrophic lateral sclerosis, the method (100) comprising the steps of: reacting carbazole with phe nylchloroformate to obtain (9-ethyl-9Hcarbazol- 3-yl)-carbamic acid phenyl ester; refluxing the resulting phenyl ester derivative with hydrazine hydrate in 1,4-dioxane to obtain a key intermediate acid hydrazide; and coupling the acid hydrazide with a 4-substituted phenyl isocyanate or 4-substituted phenyl isothiocyanate in acetonitrile under reflux to obtain a carbazole derivative compound.
2. The method (100) as claimed in claim 1, wherein step (a) is carried out in dichloromethane (DCM) in the presence of triethylamine (TEA) and the reaction mixture is stirred at room temperature for 6 hours.
3. The method (100) as claimed in claim 1, wherein step (b) comprises refluxing the phenyl ester derivative with hydrazine hydrate for 8 hours in 1,4-dioxane to yield the acid hydrazide intermediate.
4. The method (100) as claimed in claim 1, wherein the obtained carbazole derivative acts as a potential inhibitor of human superoxide dismutase 1 (hSOD1) protein aggregation for the treatment of Amyotrophic Lateral Sclerosis (ALS).
5. The method (100) as claimed in claim 4, wherein the method (100) further comprising: evaluating the anti-aggregation effects of selected carbazole derivatives in a neuronal cell-based model; testing the inhibitory potential of the synthesized carbazole derivatives against aggregation of mutant hSOD1 proteins selected from A4V, G85R, and G93A.
6. The method (100) as claimed in claim 5, wherein the generation of mutant hSOD1 proteins comprises performing PCR-based site-directed mutagenesis to introduce ALS-associated mutations into a plasmid encoding wild-type hSOD1.
7. The method (100) as claimed in claim 5, wherein the mutant hSOD1 proteins are expressed and purified using a nickel-nitrilotriacetic acid (Ni- NTA) affinity chromatography column, wherein the inhibitory activity of the carbazole derivatives is assessed by a Thioflavin T (ThT)-based fluorescence assay to monitor SOD1 aggregation kinetics.
8. The method (100) as claimed in claim 5, wherein the aggregation morphology of mutant hSOD1 proteins in the presence and absence of carbazole derivatives is evaluated using transmission electron microscopy (TEM).
7. The method (100) as claimed in claim 5, wherein the size distribution of SOD1 aggregates is determined under varying conditions using Dynamic Light Scattering (DLS) analysis.
8. The method (100) as claimed in claim 1, wherein the cell-based model comprises Neuro-2a cells stably transfected with a pCDH-hSOD1 G85R plasmid, and wherein the method (100) further includes: determining the cytotoxic effects of the carbazole derivatives on Neuro-2a cells using an MTT cell viability assay; evaluating the protective effect of the carbazole derivatives by assessing their ability to rescue Neuro-2a cells from hSOD1 G85R-induced cytotoxicity; testing the ability of the compounds to moderate hSOD1 G85Rassociated reactive oxygen species (ROS) generation in Neuro-2a cells; and evaluating the ability of the compounds to rescue Neuro-2a cells from hSOD1 G85R aggregation-induced apoptosis using Western blotting and flow cytometry (FACS) analyses.
